91.13

1.46% -1.35

Abbott Laboratories (ABT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Abbott Laboratories stock is traded at $91.13, with a volume of 12.77M. It is down -1.46% in the last 24 hours and down -12.43% over the past month. Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.

Previous Close:

$92.48

Open:

$92.15

24h Volume:

12.77M

Relative Volume:

1.03

Market Cap:

$158.35B

Revenue:

$45.13B

Net Income/Loss:

$6.28B

P/E Ratio:

25.39

EPS:

3.5895

Net Cash Flow:

$7.40B

1W Performance:

-5.87%

1M Performance:

-12.43%

6M Performance:

-28.16%

1Y Performance:

-29.56%

1-Day Range:

$91.05

$92.66

1-Week Range:

$90.72

$97.32

52-Week Range:

$90.72

$139.06

Abbott Laboratories Stock (ABT) Company Profile

Name

Abbott Laboratories

Sector

Healthcare (1108)

Industry

Medical Devices (142)

Phone

(224) 667-6100

Address

100 ABBOTT PARK ROAD, ABBOTT PARK, IL

Employee

115,000

Twitter

@AbbottNews

Next Earnings Date

2026-04-16

Latest SEC Filings

ABT's Discussions on Twitter

Compare ABT vs SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABT Abbott Laboratories	91.13	160.70B	45.13B	6.28B	7.40B	3.5895
SYK Stryker Corp	327.51	126.25B	25.12B	3.25B	4.28B	8.3984
MDT Medtronic Plc	83.32	107.58B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	62.07	97.63B	20.62B	3.56B	3.66B	2.3847
EW Edwards Lifesciences Corp	84.15	45.96B	6.07B	1.06B	1.34B	1.8063

Abbott Laboratories Stock (ABT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-10-25	Initiated	The Benchmark Company	Buy
Jul-18-25	Upgrade	Jefferies	Hold → Buy
Jun-16-25	Initiated	Leerink Partners	Market Perform
Oct-08-24	Initiated	Oppenheimer	Outperform
Sep-19-24	Initiated	Piper Sandler	Overweight
Jul-30-24	Downgrade	Edward Jones	Buy → Hold
May-30-24	Initiated	Goldman	Buy
Jul-21-23	Upgrade	Wolfe Research	Underperform → Peer Perform
May-30-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-20-23	Reiterated	Barclays	Overweight
Apr-20-23	Reiterated	Bernstein	Outperform
Apr-20-23	Reiterated	JP Morgan	Overweight
Apr-20-23	Reiterated	Raymond James	Outperform
Apr-20-23	Reiterated	UBS	Buy
Apr-20-23	Reiterated	Wolfe Research	Underperform
Mar-29-23	Initiated	UBS	Buy
Oct-26-22	Initiated	Mizuho	Neutral
Oct-18-22	Initiated	Barclays	Overweight
Oct-12-22	Initiated	Jefferies	Hold
Jul-06-22	Initiated	Wolfe Research	Underperform
Mar-02-22	Resumed	BofA Securities	Buy
Jan-27-22	Reiterated	Credit Suisse	Outperform
Jan-27-22	Reiterated	Morgan Stanley	Overweight
Jan-27-22	Reiterated	Raymond James	Outperform
Jan-27-22	Reiterated	UBS	Buy
Dec-10-21	Initiated	RBC Capital Mkts	Outperform
Oct-27-21	Upgrade	Atlantic Equities	Neutral → Overweight
Oct-14-21	Initiated	Redburn	Neutral
May-25-21	Initiated	Barclays	Overweight
Apr-15-21	Initiated	Atlantic Equities	Neutral
Jan-28-21	Upgrade	BTIG Research	Neutral → Buy
Sep-11-20	Initiated	Wolfe Research	Outperform
Jun-01-20	Downgrade	Goldman	Neutral → Sell
Mar-05-20	Initiated	Citigroup	Buy
Feb-13-20	Initiated	Goldman	Neutral
Feb-06-20	Resumed	BTIG Research	Neutral
Jan-02-20	Downgrade	Guggenheim	Buy → Neutral
Jun-13-19	Reiterated	BofA/Merrill	Buy
Feb-07-19	Reiterated	BofA/Merrill	Buy
Jan-02-19	Downgrade	Citigroup	Neutral → Sell
Nov-30-18	Upgrade	Goldman	Neutral → Buy
Oct-16-18	Initiated	Barclays	Overweight
Jun-27-18	Initiated	Bernstein	Outperform
Jan-30-18	Reiterated	Citigroup	Neutral
Jan-25-18	Reiterated	Stifel	Buy
Jan-25-18	Upgrade	William Blair	Mkt Perform → Outperform
Jan-03-18	Initiated	Evercore ISI	Outperform
Jan-02-18	Upgrade	JP Morgan	Neutral → Overweight
Jan-02-18	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-19-17	Reiterated	RBC Capital Mkts	Outperform
Oct-19-17	Reiterated	Stifel	Buy

View All

Abbott Laboratories Stock (ABT) Latest News

05:55 AM

M&T Bank Corp Decreases Holdings in Abbott Laboratories $ABT - MarketBeat

05:55 AM

02:13 AM

Is There Now An Opportunity In Abbott Laboratories (ABT) After Recent Share Price Pullback? - simplywall.st

02:13 AM

Apr 24, 2026

A Look At Abbott Laboratories ABT Valuation After New Cancerguard Early Cancer Detection Data - Yahoo Finance

Apr 24, 2026

Abbott Laboratories stock underperforms Friday when compared to competitors - MarketWatch

Apr 24, 2026

Daiwa Downgrades Abbott Laboratories (ABT), Sees Limited Upside - Yahoo Finance

Apr 24, 2026

Abbott Laboratories: Buying A Healthcare Giant On Sale (NYSE:ABT) - Seeking Alpha

Apr 24, 2026

Apr 23, 2026

Why Abbott’s S&P 500 Fund Oncology Story Is Turning Heads? - Kalkine Media

Apr 23, 2026

symbol__ Stock Quote Price and Forecast - CNN

Apr 23, 2026

Abbott CancerGuard Data And AACR Award Add To Oncology Growth Story - simplywall.st

Apr 23, 2026

Catheters Market Report 2025-2030, Profiles and Strategy Analysis of Leading PlayersAbbott Laboratories, Boston Scientific, Medtronic, Terumo, and B. Braun - Yahoo Finance

Apr 23, 2026